Therefore, HMGA2 could be an excellent candidate as a therapeutic target because it is involved at various levels in the pathogenesis of MPN, including the regulation of gene expressions and the hematopoietic clonal proliferation [127]. This evidence concerns the gene HMGA2 and myeloproliferative disorder.